

Balaxi Pharmaceuticals Limited

August 04, 2023

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Newspaper Advertisement – Disclosure under Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisement published today i.e., August 04, 2023, regarding the financial results of the Company for the quarter ended June 30, 2023, as published in Business Standard (English) and Nava Telangana (Telugu) newspapers.

The aforesaid information is also being hosted on the Company's website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,

For Balaxi Pharmaceuticals Limited

Udayan Shukla
(Company Secretary and Compliance Officer)
Membership No.: F11744

Encl: A/a

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

BSE Limited website at www.bseindia.com and on the website of the Company
 Agreement dated February 24, 2023 and Letter of Offer dated May 1, 2023 and
 ons 13(1) and 15(1) of the Securities and Exchange Board of India (Substantial
 2011, as amended ("SEBI (SAST) Regulations") the Management as well as
 nged.

For, Yuranus Infrastructure Limited
 Sd/-
 Nitinbhai Govindbhai Patel
 Additional Director
 DIN: 06626646

September 2, 2023 to Friday, September 8, 2023 (both days inclusive) for the purpose of 31st
 AGM for the financial year 2022-23.
 For detailed instructions pertaining to E-Voting, members may please refer Notes to the
 Notice of 31st AGM. Members facing any technical issue in login before / during the AGM can
 contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at Toll Free No.:
 022-4886 7000 and 022-2499 7000.

For **RISHI LASER LIMITED**

Date : 03.08.2023
 Place : Mumbai

Sd/-
Harshad Patel
 Managing Director
 Rameshwar Media

Balaxi Pharmaceuticals Limited

Registered Office: 3rd Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.
 CIN: L25191TG1942PLC121598
 Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2023

(Rs. in Lakhs, unless specified)

Sl. No.	Particulars	STANDALONE				CONSOLIDATED			
		Quarter ended 30/06/2023 Unaudited	Quarter ended 31/03/2023 Audited	Quarter ended 30/06/2022 Unaudited	Year ended 31/03/2023 Audited	Quarter ended 30/06/2023 Unaudited	Quarter ended 31/03/2023 Audited	Quarter ended 30/06/2022 Unaudited	Year ended 31/03/2023 Audited
1.	Total Income from Operations	2,504.03	3,035.14	2,645.36	10,813.76	6,595.54	8,068.12	8,278.49	33,643.26
2.	Net profit/(loss) for the period (before tax, exceptional* and/or extraordinary items)	350.84	508.73	653.28	2,245.05	725.73	1,106.83	1,664.85	5,692.23
3.	Net profit/(loss) for the period before tax (after exceptional* and/or extraordinary items)	350.84	508.73	653.28	2,245.05	(3,941.21)	1,106.83	1,664.85	5,692.23
4.	Net profit/(loss) for the period after tax (after exceptional* and/or extraordinary items)	255.42	394.31	533.52	1,622.21	(4,134.3)	810.03	1,414.66	4,596.25
5.	Total Comprehensive Income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	255.42	394.31	533.52	1,622.21	(3,621.81)	791.55	1,655.25	5,174.44
6.	Paid-up Equity Share Capital [Face value of Rs. 10 each]	1,023.02	1,018.13	1,000.00	1,018.13	1,023.02	1,000.00	1,000.00	1,018.13
7.	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year				7,162.83				16,240.16
8.	Earnings Per Share (of Rs.10/- each)								
	1. Basic (amount in Rs.)	2.50	3.90	5.34	16.17	(40.49)	8.01	14.15	45.81
	2. Diluted (amount in Rs.)	2.47	3.83	5.34	16.02	(39.93)	7.86	14.15	45.40

Notes:

- The above is an extract of the detailed format of Financial Results for the quarter ended June 30, 2023, filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Unaudited Standalone and Consolidated Financial Results is available on the website of the Stock Exchange at www.nseindia.com (NSE) and on the Company's website at www.balaxipharma.in.
- The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 03, 2023. The said Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.
- *With respect to the Consolidated Financial Results, During the quarter under review, the Angolan currency Kwanzas underwent an unprecedented sharp depreciation, falling from 511.50 AOA/USD to 832.5 AOA/USD. Since the creditors in the books of Balaxi Angola are contracted in and due for settlement in USD, this has resulted in a loss on revaluation of 3.65bn AOA (INR 46.66 cr.) including unrealised loss of 3.46bn AOA (INR 44.35 cr.) as of June 30, 2023. The corresponding INR amount has been shown as an exceptional item in the profit and loss statement for the quarter. Balaxi Healthcare Angola has taken several price corrections during the quarter and inventories lying in the books (carried at historical cost as per conservative accounting principles) is now being sold at much higher prices.

Place: Hyderabad
 Date: August 03, 2023

For and on behalf of Board of Directors,
Balaxi Pharmaceuticals Limited

Ashish Maheshwari
 Managing Director
 DIN: 01575984

